PEN
Penumbra
October 15, 2026 · after-hours
- Rarity
- 2.89
- Peak move
- +2.40%
- Float cap
- —
Penumbra is a medical device company that designs, manufactures, and markets thrombectomy, embolization, and vascular access products for specialist physicians. Its computer-assisted vacuum thrombectomy systems and neurovascular tools treat blood clots and aneurysms in conditions such as ischemic stroke, pulmonary embolism, deep vein thrombosis, and acute limb ischemia. It sells directly to hospitals and clinics in the United States, Europe, Canada, Australia, and Singapore, and through distributors elsewhere.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
2 events · 0 from SEC or newswire · 0 timed with the moveclinical_readoutPenumbra completed enrollment in its THUNDER IDE clinical study evaluating the Penumbra System with Thunderbolt aspiration tubing (computer assisted vacuum thrombectomy) for removing blood clots in acute ischemic stroke caused by large vessel occlusion.
guidance_changePenumbra said it will not provide full-year 2026 guidance and will not hold its customary quarterly earnings conference call because of the pending acquisition by Boston Scientific.